Efficacy of ferric carboxymaltose for the treatment of IBD-related iron deficiency anaemia

Trial Profile

Efficacy of ferric carboxymaltose for the treatment of IBD-related iron deficiency anaemia

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Dec 2016

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Iron deficiency anaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Dec 2016 New trial record
    • 19 Oct 2016 Primary endpoint of normalisation of serum ferritin and transferrin saturation has been met, according to results presented at the 24th United European Gastroenterology Week.
    • 19 Oct 2016 Primary endpoint of normalisation of Hb or increase of 2 g/dL has been met, according to results presented at the 24th United European Gastroenterology Week.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top